Stock listing
NASDAQ:TLSA Tiziana Life Sciences Ltd Stock
Home listing (NASDAQ) of Tiziana Life Sciences Ltd
Follow Tiziana Life Sciences Ltd into a list and get an email when it puts out news.
Share price · NASDAQ:TLSA
$0.621 USD -0.059 (-8.7%)
Close on Nov 20, 2026
- Day range
- $0.612 – $0.700 USDNov 20, 2026
- Volume
- 231,243 sharesNov 20, 2026
- Market cap
- $78.98M USDAt the close on Nov 20, 2026 · price × 127.3M shares outstanding
- 52-week range
- $0.550 – $1.900 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $586,725 USDMedian day 490,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TLSA · Home | $0.621 USD | -0.059 (-8.7%) | 231,243 | $0.690 | $0.700 | $0.612 | $0.680 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TLSA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.621 | -0.059 | -8.7% | $0.690 | $0.700 | $0.612 | 231,243 | |
| $0.680 | -0.130 | -16.0% | $0.790 | $0.800 | $0.680 | 339,100 | |
| $0.810 | +0.160 | +24.6% | $0.670 | $0.840 | $0.650 | 1,280,900 | |
| $0.650 | +0.070 | +12.1% | $0.580 | $0.750 | $0.580 | 740,000 | |
| $0.580 | +0.010 | +1.8% | $0.570 | $0.610 | $0.550 | 665,300 | |
| $0.570 | -0.040 | -6.6% | $0.600 | $0.630 | $0.570 | 266,500 | |
| $0.610 | -0.010 | -1.6% | $0.630 | $0.650 | $0.610 | 194,200 | |
| $0.620 | +0.010 | +1.6% | $0.640 | $0.660 | $0.610 | 359,600 | |
| $0.610 | -0.060 | -9.0% | $0.680 | $0.680 | $0.610 | 395,100 | |
| $0.670 | -0.020 | -2.9% | $0.700 | $0.700 | $0.660 | 305,500 | |
| $0.690 | +0.070 | +11.3% | $0.620 | $0.700 | $0.620 | 324,500 | |
| $0.620 | -0.020 | -3.1% | $0.660 | $0.660 | $0.570 | 766,200 | |
| $0.640 | -0.050 | -7.2% | $0.700 | $0.710 | $0.620 | 420,900 | |
| $0.690 | +0.020 | +3.0% | $0.660 | $0.730 | $0.650 | 539,500 | |
| $0.670 | -0.130 | -16.3% | $0.840 | $0.860 | $0.620 | 2,849,700 | |
| $0.800 | -0.100 | -11.1% | $0.900 | $0.920 | $0.790 | 1,292,100 | |
| $0.900 | -0.050 | -5.3% | $0.950 | $0.950 | $0.900 | 187,600 | |
| $0.950 | +0.080 | +9.2% | $0.890 | $0.960 | $0.880 | 250,700 | |
| $0.870 | -0.010 | -1.1% | $0.880 | $0.940 | $0.870 | 189,400 | |
| $0.880 | -0.070 | -7.4% | $0.950 | $0.950 | $0.860 | 377,700 | |
| $0.950 | -0.050 | -5.0% | $0.970 | $0.980 | $0.930 | 252,000 | |
| $1.000 | -0.010 | -1.0% | $0.980 | $1.010 | $0.940 | 494,000 | |
| $1.010 | 0.000 | 0.0% | $1.030 | $1.030 | $0.970 | 421,500 | |
| $1.010 | 0.000 | 0.0% | $1.020 | $1.030 | $0.990 | 299,200 | |
| $1.010 | -0.040 | -3.8% | $1.060 | $1.070 | $0.990 | 332,500 | |
| $1.050 | 0.000 | 0.0% | $1.080 | $1.100 | $1.030 | 558,800 | |
| $1.050 | 0.000 | 0.0% | $1.050 | $1.070 | $1.020 | 264,400 | |
| $1.050 | -0.040 | -3.7% | $1.060 | $1.080 | $1.030 | 581,400 | |
| $1.090 | 0.000 | 0.0% | $1.090 | $1.120 | $1.050 | 492,600 | |
| $1.090 | -0.100 | -8.4% | $1.200 | $1.200 | $1.070 | 567,600 | |
| $1.190 | +0.060 | +5.3% | $1.140 | $1.250 | $1.130 | 2,423,400 | |
| $1.130 | +0.030 | +2.7% | $1.110 | $1.150 | $1.110 | 449,900 | |
| $1.100 | -0.010 | -0.9% | $1.110 | $1.140 | $1.070 | 384,600 | |
| $1.110 | +0.040 | +3.7% | $1.080 | $1.140 | $1.050 | 628,200 | |
| $1.070 | -0.050 | -4.5% | $1.120 | $1.140 | $1.070 | 274,400 | |
| $1.120 | -0.020 | -1.8% | $1.160 | $1.200 | $1.100 | 436,800 | |
| $1.140 | +0.030 | +2.7% | $1.110 | $1.190 | $1.090 | 697,700 | |
| $1.110 | +0.160 | +16.8% | $1.000 | $1.140 | $0.970 | 1,518,700 | |
| $0.950 | -0.030 | -3.1% | $0.980 | $1.030 | $0.940 | 511,300 | |
| $0.980 | -0.030 | -3.0% | $1.010 | $1.050 | $0.960 | 389,000 | |
| $1.010 | -0.030 | -2.9% | $1.030 | $1.080 | $1.000 | 382,700 | |
| $1.040 | -0.010 | -1.0% | $1.100 | $1.110 | $1.000 | 706,600 | |
| $1.050 | +0.160 | +18.0% | $0.890 | $1.060 | $0.890 | 1,573,700 | |
| $0.890 | -0.010 | -1.1% | $0.890 | $0.890 | $0.870 | 623,900 | |
| $0.900 | -0.010 | -1.1% | $0.940 | $0.950 | $0.900 | 534,300 | |
| $0.910 | -0.060 | -6.2% | $0.970 | $0.980 | $0.910 | 414,800 | |
| $0.970 | +0.200 | +26.0% | $0.850 | $1.010 | $0.850 | 1,743,200 | |
| $0.770 | -0.080 | -9.4% | $0.850 | $0.880 | $0.760 | 844,100 | |
| $0.850 | -0.040 | -4.5% | $0.890 | $0.890 | $0.810 | 659,200 | |
| $0.890 | -0.070 | -7.3% | $0.960 | $0.980 | $0.880 | 564,200 | |
| $0.960 | 0.000 | 0.0% | $0.980 | $1.000 | $0.930 | 272,900 | |
| $0.960 | -0.020 | -2.0% | $0.960 | $0.980 | $0.950 | 194,600 | |
| $0.980 | -0.010 | -1.0% | $0.990 | $1.010 | $0.950 | 245,500 | |
| $0.990 | -0.030 | -2.9% | $1.020 | $1.030 | $0.960 | 908,200 | |
| $1.020 | +0.050 | +5.2% | $0.970 | $1.060 | $0.950 | 573,900 | |
| $0.970 | +0.040 | +4.3% | $1.050 | $1.050 | $0.950 | 517,900 | |
| $0.930 | -0.030 | -3.1% | $0.960 | $1.000 | $0.910 | 487,800 | |
| $0.960 | -0.030 | -3.0% | $0.990 | $1.000 | $0.910 | 515,100 | |
| $0.990 | -0.020 | -2.0% | $1.020 | $1.050 | $0.970 | 429,700 | |
| $1.010 | -0.070 | -6.5% | $1.100 | $1.100 | $1.000 | 565,500 | |
| $1.080 | -0.010 | -0.9% | $1.090 | $1.140 | $1.050 | 272,300 | |
| $1.090 | -0.020 | -1.8% | $1.120 | $1.130 | $1.080 | 402,600 | |
| $1.110 | -0.040 | -3.5% | $1.180 | $1.180 | $1.100 | 441,000 | |
| $1.150 | +0.010 | +0.9% | $1.140 | $1.250 | $1.140 | 959,000 | |
| $1.140 | +0.020 | +1.8% | $1.120 | $1.170 | $1.090 | 832,300 | |
| $1.120 | +0.050 | +4.7% | $1.080 | $1.160 | $1.040 | 1,573,000 |
Splits
2 splits since 2019 · NASDAQ:TLSA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2.499-for-1 | Split | |
| 2-for-1 | Split |
- Ticker
- NASDAQ:TLSA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London
Latest deck · Nov 9, 2026
Technical Presentation (November 2026)
Technical · 20 slides
Latest news
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London
Nov 12, 2026
Closed $0.61 (-1.6%) on Nov 12, 2026
Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab
Nov 9, 2026
Closed $0.67 (-2.9%) on Nov 9, 2026
Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intran...
Nov 9, 2026
Closed $0.67 (-2.9%) on Nov 9, 2026
Tiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast
Nov 9, 2026
Closed $0.67 (-2.9%) on Nov 9, 2026
Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results
Nov 5, 2026
Closed $0.62 (-3.1%) on Nov 5, 2026
Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
Nov 2, 2026
Closed $0.67 (-16.3%) on Nov 2, 2026
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
Oct 21, 2026
Closed $1.01 (0.0%) on Oct 21, 2026
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
Oct 16, 2026
Closed $1.05 (0.0%) on Oct 16, 2026
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
Sep 30, 2026
Closed $1.11 (+16.8%) on Sep 30, 2026
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
Sep 28, 2026
Closed $0.98 (-3.0%) on Sep 28, 2026
Tiziana Life Sciences Ltd on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 42 in the last 12 months · 202 in all · newest Nov 12, 2026 · oldest 2020
- Decks
- 17 decks · latest Nov 9, 2026
Where Tiziana Life Sciences Ltd is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TLSA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TLSA | BOATS | United States | USD |
| Lang & Schwarz:A3C5SS | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3C5SS | LS Exchange | Germany | EUR |
| gettex:0RP | gettex | Germany | EUR |
| Frankfurt:0RP | Frankfurt | Germany | EUR |
| Dusseldorf:0RP | Dusseldorf | Germany | EUR |
| Munich:0RP | Munich | Germany | EUR |
| Stuttgart:0RP | Stuttgart | Germany | EUR |
| Tradegate:0RP | Tradegate | Germany | EUR |
Valuation
Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $76.73M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.23
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd · NASDAQ:TLSA | US$78.98M | US$76.73M | n/a | n/a | n/a | n/a | n/a | n/a | 1.23 |
| 3D Medicines, Inc. · HKEX:1244 | US$81.88M | US$48.45M | n/a | 0.9× | n/a | 1.0× | −49.9% | 0.3× | n/a |
| Kintor Pharmaceutical Ltd · HKEX:9939 | US$81.70M | US$96.94M | n/a | 19.8× | n/a | 5.0× | −612.3% | 1.2× | n/a |
| Nkarta, Inc. · NASDAQ:NKTX | US$81.38M | −US$75.22M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.67 |
| Captor Therapeutics SA · GPW:CTX | US$81.11M | US$64.15M | n/a | 130× | n/a | 5.1× | n/a | 0.0× | n/a |
| Vaxart, Inc. · OTC:VXRT | US$79.89M | US$14.34M | 2.8× | 0.1× | 0.4× | 1.2× | 16.0% | 0.0× | 1.21 |
| Sensorion SAS · EURONEXT:ALSEN | US$79.63M | −US$13.98M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| Adocia SA · EURONEXT:ADOC | US$79.30M | US$77.84M | n/a | 48.1× | n/a | n/a | n/a | n/a | n/a |
| Nyrada, Inc. · ASX:NYR | US$78.76M | US$73.21M | n/a | n/a | n/a | 12.5× | n/a | 0.0× | n/a |
| TiumBio Co., Ltd. · KRX:321550 | US$77.24M | US$60.57M | n/a | 5.4× | n/a | 2.9× | −114.1% | 0.3× | n/a |
| HLB Therapeutics Co., Ltd. · KRX:115450 | US$76.82M | US$66.93M | n/a | 1.4× | n/a | 0.7× | −28.0% | 0.0× | n/a |
| Median of the others | US$79.76M | US$62.36M | 2.8× | 5.4× | 0.4× | 1.2× | −49.9% | 0.0× | 1.44 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.87 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.13 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ivor Elrifi | Chief Executive Officer & Executive Director |
| Keeren Shah | Chief Operating Officer & Chief Financial Officer |
| Paul Spencer | Business Development, and Investor Relations |
| Gabriele Cerrone | Executive Chairman |
| Richard Kim | Chief Medical Officer |
| William Tente | Chief Regulatory Officer |
Board
| Director | Role |
|---|---|
| Gabriele Cerrone | Executive Chairman |
| Ivor Elrifi | Chief Executive Officer & Executive Director |
| John Brancaccio | Non-Executive Director |
| Willy Simon | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2025 | Oct 3, 2025 | −1.5% |
| Q1 2025 | Jun 23, 2025 · After close | +1.9% |
| Q3 2024 | Oct 18, 2024 | −4.4% |
| Q3 2022 | Dec 27, 2022 · After close | +1.8% |
| Q1 2022 | May 22, 2022 · After close | −17.4% |
| Quarter to Sep 30, 2021 | Dec 1, 2021 | −7.9% |
| Quarter to Jun 30, 2021 | Sep 24, 2021 · After close | +4.0% |
| Quarter to Mar 31, 2021 | May 17, 2021 · After close | −1.8% |
| Quarter to Dec 31, 2020 | Mar 31, 2021 | −2.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2026) | Technical | 20 slides | Nov 9, 2026 |
| Investor Presentation (May 2026) | Investor deck | 18 slides | May 2026 |
| Investor Presentation (2026) | Investor deck | 19 slides | 2026 |
| IPO Roadshow (December 2025) | IPO roadshow | 21 slides | Dec 12, 2025 |
| Investor Presentation (December 2025) | Investor deck | 18 slides | December 2025 |
| Investor Presentation (September 2025) | Investor deck | 18 slides | September 2025 |
| Investor Presentation (July 2025) | Investor deck | 16 slides | July 2025 |
| Investor Presentation (March 2025) | Investor deck | 20 slides | March 2025 |
| Investor Presentation (August 2024) | Investor deck | 24 slides | August 2024 |
| Investor Presentation (May 2024) | Investor deck | 24 slides | May 2024 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2023) | Investor deck | 25 slides | October 2023 |
| Investor Presentation (September 2023) | Investor deck | 24 slides | September 2023 |
| Investor Presentation (March 2023) | Investor deck | 20 slides | March 2023 |
| Investor Presentation (October 2022) | Investor deck | 28 slides | Oct 25, 2022 |
| Investor Presentation (August 2020) | Investor deck | 27 slides | August 2020 |
| IPO Roadshow (August 2019) | IPO roadshow | 30 slides | Aug 6, 2019 |
| IPO Roadshow (September 2018) | IPO roadshow | 36 slides | Sep 25, 2018 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of ordinary shares Closed: US$8.8M raised · US$1.25 a share · 1 warrant at US$1.5 Buyers: Ivor Elrifi (2,400,000 ordinary shares, bringing his total holding to 2,757,848 ordinary shares); Gabriele Cerrone (through Panetta Partners Ltd) (1,600,000 ordinary shares, bringing his total holdings to 44,974,830 ordinary shares) Insiders: Led by CEO Ivor Elrifi, who bought 2,400,000 shares; Executive Chairman Gabriele Cerrone bought 1,600,000 shares through Panetta Partners Ltd Use of proceeds: Complete Phase 2 na-SPMS and MSA clinical trials and achieve top line data readouts in both | Jan 16, 2026 |
| Public offering of common shares Cancelled: public offering | Dec 15, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$9.90 an ADS on Nov 20, 2018.
- Price
- US$9.90 an ADS
- ADSs offered
- 442,910 American depositary shares
- Offering size
- US$4.4 million
- Underwriters' option
- Up to 66,437 more ADSs
- Listing
- TLSA on the Nasdaq Global Market
- Underwriter
- Laidlaw & Company (UK) Ltd.
- ADSs delivered
- On or about Nov 23, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 30, 2017 |
| Filed publicly | Jul 26, 2018 |
| Amended 6 times | Newest Nov 14, 2018 |
| Shares registered with an exchange | Oct 30, 2018 |
| Declared effective by the SEC | Nov 19, 2018 |
| Final prospectus, with the price | Nov 21, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 21, 2018 |
| EFFECT · Notice that a registration is effective | Nov 19, 2018 |
| CORRESP · Letter to the SEC | Nov 19, 2018 |
| CORRESP · Letter to the SEC | Nov 19, 2018 |
| POS AM · Amendment to an effective registration | Nov 14, 2018 |
| EFFECT · Notice that a registration is effective | Nov 9, 2018 |
| CORRESP · Letter to the SEC | Nov 9, 2018 |
| CORRESP · Letter to the SEC | Nov 9, 2018 |
| CORRESP · Letter to the SEC | Nov 7, 2018 |
| CORRESP · Letter to the SEC | Nov 7, 2018 |
All 56 filings
Open IPO · From the cover of the final prospectus (424B4) filed Nov 21, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 234.0K | 14.6M | 141.0K | 89.8K | 250.0K | 16.0K | 10.7K | 8.79K | ||
| Gross profit | -234.0K | -14.6M | -141.0K | -89.8K | -250.0K | -16.0K | -10.7K | -8.79K | ||
| Research and development | 10.3M | 5.23M | 8.11M | 13.0M | 13.2M | 5.99M | 3.71M | 5.51M | 6.01M | 4.01M |
| Selling, general and administrative | 10.9M | 10.6M | 9.87M | 1.63M | 1.15M | 18.0M | 6.21M | 4.42M | 72.0M | 33.6M |
| Operating income | -21.1M | -15.8M | -18.0M | -14.6M | -27.4M | -28.0M | -9.92M | -9.87M | -10.5M | -9.88M |
| Depreciation and amortization | 234.0K | 12.0K | 7.00K | 1.00K | 8.00K | 5.00K | 5.00K | 16.0K | 13.0K | 11.0K |
| EBITDA | -20.9M | -15.8M | -18.0M | -14.6M | -27.4M | -28.0M | -9.92M | -9.85M | -10.5M | -9.87M |
| Interest expense | 18.0K | 1.77M | 412.0K | 876.0K | 237.4K | 435.3K | 92.0K | 12.0K | 12.0K | 12.0K |
| Income before tax | -18.4M | -16.7M | -17.2M | -15.4M | -26.7M | -28.3M | -10.0M | -9.88M | -10.5M | -9.89M |
| Income tax | -4.88M | 449.0K | 811.0K | -3.24M | -2.21M | -2.21M | -1.95M | -1.91M | -121.0K | |
| Net income | -18.4M | -11.9M | -17.7M | -15.4M | -23.4M | -26.1M | -9.32M | -7.93M | -8.59M | -9.77M |
| Earnings per share, basic | -0.16 | -0.11 | -0.17 | -0.15 | -0.24 | -0.16 | -0.07 | -0.06 | -8.59 | -11.35 |
| Earnings per share, diluted | -0.11 | -0.17 | -0.15 | -0.24 | -0.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.01M | 3.72M | 1.18M | 18.1M | 42.2M | 65.8M | 200.0K | 5.30M | 64.0K | 5.80M |
| Short-term investments | 0 | 1000000.0T | 1000000.0T | |||||||
| Receivables | 4.26M | 3.69M | 6.05M | 5.86M | 5.27M | 3.78M | 1.29M | 1.29M | 1.55M | 93.6K |
| Inventory | -5.99M | -5.31M | -2.28K | -1.29M | 0 | 0 | 0 | |||
| Current assets | 8.55M | 7.51M | 7.34M | 24.3M | 48.7M | 70.2M | 1.50M | 6.91M | 2.45M | 5.02M |
| Property, plant and equipment | 16.0K | 10.0K | 17.0K | 17.0K | 3.00K | 6.00K | 7.00K | 23.0K | 28.0K | |
| Goodwill | -35.6K | 0 | 0 | 0 | ||||||
| Total assets | 11.5M | 11.3M | 12.2M | 26.5M | 48.8M | 70.7M | 2.38M | 6.92M | 2.47M | 5.05M |
| Accounts payable | 7.17M | 7.23M | 6.39M | 6.53M | 6.18M | 5.59M | 6.40M | 5.95M | 4.42M | 2.14M |
| Current liabilities | 11.2M | 7.35M | 6.54M | 6.66M | 7.55M | 7.98M | 7.35M | 6.40M | 4.75M | 1.74M |
| Long-term debt | 0 | 0 | 0 | |||||||
| Total debt | 456.0K | 106.0K | 247.0K | 365.0K | 1.35M | 324.0K | 313.0K | 302.0K | 290.0K | 278.0K |
| Total liabilities | 11.4M | 7.35M | 6.65M | 6.91M | 7.55M | 8.27M | 7.89M | 6.40M | 4.75M | 1.74M |
| Shareholders' equity | 52.0K | 3.94M | 5.54M | 19.6M | 41.3M | 62.4M | 69.6M | 75.8M | -2.28M | 4.09M |
| Shares outstanding | 118.3M | 106.7M | 102.5M | 101.5M | 97.9M | 97.3M | 136.5M | 136.5M | 117.0M | 106.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12.8M | -1.53M | -15.7M | -19.6M | -21.8M | -11.3M | -6.80M | -4.60M | -7.53M | -5.62M |
| Capital spending | -21.0K | -19.0K | 0 | 0 | -22.0K | -3.00K | -4.00K | -1 | -1.00K | -48.0K |
| Free cash flow | -12.9M | -1.54M | -12.4M | -16.0M | -21.8M | -11.3M | -6.80M | -4.60M | -7.53M | -5.65M |
| Cash from investing | 3.04M | -71.0K | -1.25M | -4.00M | 130.0K | -123.0K | -4.00K | -788 | -1.00K | -342.0K |
| Cash from financing | 10.0M | 4.50M | 40.0K | -55.0K | -23.0K | 75.3M | 1.68M | 10.1M | 1.54M | 1.57M |
| Dividends paid | 0 | 0 | 0 | |||||||
| Share buybacks | 1.47M | 8.57M | 1.20M | 453.0K | ||||||
| Change in cash | 286.0K | 2.91M | -16.9M | -23.7M | -21.7M | 63.9M | -5.12M | 5.49M | -5.99M | -5.69M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 5, 2026 | Current report | SEC |
| 6-K/A · Report of a foreign issuer, amended | Nov 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 21, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 16, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 496 filings. Open Filings
Cap table
Built by 6ix from Tiziana Life Sciences Ltd’s releases · as of Jan 16, 2026
- Common shares
- 127,259,131
- Fully diluted
- 134,299,131
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 127,259,131 | |
| Warrants | 7,040,000 | Jan 16, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.50 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 127,259,131 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gabriele Cerrone Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 5, 2026); OKYO Pharma Limited (Non-Executive Chairman · Since at least Jul 21, 2026) | Executive Chairman · Since at least Jun 15, 2026 |
| John Brancaccio Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 5, 2026); OKYO Pharma Limited (Director · Since at least Mar 18, 2026) | Non-Executive Director · Since at least Nov 5, 2026 |
| Keeren Shah Other companies: OKYO Pharma Limited (Chief Financial Officer · Since at least May 16, 2022); Accustem Sciences Inc (Chief Finance Officer · Since at least Dec 1, 2021) | Chief Operating Officer & Chief Financial Officer · Since at least Mar 18, 2026 |
| Willy Simon Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 4, 2026); OKYO Pharma Limited (Non-Executive Director · Since at least Nov 4, 2026) | Non-Executive Director · Since at least Nov 4, 2026 |
| Paul Spencer Other companies: OKYO Pharma Limited (Business Development and Investor Relations · Since at least Oct 6, 2026) | Business Development, and Investor Relations · Since at least Oct 21, 2026 |
| Ivor Elrifi | Chief Executive Officer & Executive Director · Since at least Mar 18, 2026 |
| Richard Kim | Chief Medical Officer · Since at least Nov 5, 2026 |
| William Tente | Chief Regulatory Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Tiziana Life Sciences Ltd.